Trial Profile
"Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients With Non-severe Fibrosis, With or Without Glucose Abnormalities - EGG 18"
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms EGG18
- 21 Feb 2023 Status changed from recruiting to completed.
- 01 Aug 2022 Results published in the Digestive and Liver Disease
- 16 Apr 2018 New trial record